"Your Partner of Choice and your gate to the Middle East and North Africa (MENA) Pharmaceutical World"


Genpharm Services is a financially sound privately owned company based in the Dubai Science Park (DSP), U.A.E. We provide fast-track Market Access to specialty pharmaceutical companies looking to expand into the Middle East and North Africa (MENA) region. We focus on innovative and orphan drugs in areas of unmet medical needs, rare genetic disorders and autoimmune diseases.

Pharmaceutical Strategic Advice

"We also provide Management Consultancy for companies aiming at expanding directly into this dynamic region of high growth. We advise on strategies, structures and operating business models in line with the respective company priorities and portfolio. "

DIF Healthcare Panel features Genpharm CEO

Genpharm CEO Mr. Karim Smaira in the Healthcare spotlight panel of the Dubai Investment Forum.

Is this the Era of Biosimilars?

According to reports from IMS Health and Deloitte, biologics are already a $150-billion-plus industry globally and are expected to double by 2020, accounting for more than 27% of the pharmaceutical market. Analysts also expect the worldwide biosimilars market to grow, reaching approximately $35 billion by 2020. The Middle East and Africa Biosimilars Market was worth $0.37 billion in 2016 and estimated to be growing at a CAGR of 32%, to reach $1.63 billion by 2021, according to a report from Market Data Forecast. The MENA region can be considered as influential and attractive pharmaceutical markets among other emerging markets.

His Excellency Sheikh Nahyan bin Mubarak Al Nahyan honoring Genpharm for their role in raising awareness on Rare Diseases and for their contribution on Rare Disease Day

His Excellency Sheikh Nahyan bin Mubarak Al Nahyan, Minister of Culture and the development of knowledge, president of the UAE Genetic Diseases Association, honored several specialized experts in rare diseases, as part of the annual Emirates International Award for reducing genetic diseases "rare disease category" in its third session.

Aspire Educational Series: OlivoPontoCerebellar Atrophy (OPCA)- Part 22

Olivopontocerebellar atrophy can be passed down through families (inherited form), or it may affect people without a known family history (sporadic form). Researchers have identified certain genes that are involved in the inherited form of this condition. In this disease brain cell of the particular part of brain namely the pons, cerebellum and inferior olive begin to degenerate and die.